• Addex Therapeutics will hold its 2026 annual general meeting in Geneva on June 29, 2026.
• Shareholders will vote on the 2025 annual report, standalone financial statements, consolidated financial statements, compensation report, and profit appropriation.
• Resolutions include discharge of the board and executive management, board and chairman re-elections, compensation committee re-elections, and auditor re-election.
• Proposals also cover re-election of the independent voting rights representative and amendments to the articles to expand the capital band and conditional share capital.
• Votes are scheduled on compensation for the board of directors and the executive management.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Addex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606050100PRIMZONEFULLFEED1001186014) on June 05, 2026, and is solely responsible for the information contained therein.